{"product_id":"global-personalized-medicine-market-size-study-forecast-by-product-personalized-medicine-diagnostics-personalized-medicine-therapeutics-personalized-medical-care-personalized-nutrition-wellness-and-regional-analysis-2022-2029","title":"Global Personalized Medicine Market Size study \u0026 Forecast, by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition \u0026 Wellness) and Regional Analysis, 2022-2029","description":"\u003cp\u003eGlobal Personalized Medicine Market Size study \u0026amp; Forecast, by Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Medical Care, Personalized Nutrition \u0026amp; Wellness) and Regional Analysis, 2022-2029\u003c\/p\u003e\n\n\u003cp\u003eGlobal Personalized Medicine Market is valued approximately USD 514.33 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.95% over the forecast period 2022-2029. Personalised medicine, is also known as precision medicine, it divides people into distinct groups and then tailors medical decisions, therapies, practises, and\/or products to each patient depending on that patient's expected response or illness risk. The market is majorly driven by rising demand for novel drug discovery, rising number of cancer cases and other diseases. Along with this, growing number of clinical trials is driving the growth for the market over the forecast period 2022-2029. Moreover, rising initiatives by key market players is creating lucrative growth opportunity for the market over the period.\u003c\/p\u003e\n\n\u003cp\u003eIt is also projected that the rising prevalence of rare diseases will accelerate market expansion. The development of numerous individualized medical treatments and therapeutic activities has been made possible by advances in our understanding and correlation of the properties of the human genome. For instance, a research study conducted at the University of California, Irvine in September 2022 offered a unique method for treating inherited retinal diseases (IRDs) by applying precise genome editing that is highly tailored to the needs of an individual. Along with this, there are an increasing number of companion diagnostics that have received FDA approval. For example, Roche received U.S. FDA clearance in October 2020 to expand the use of the Cobas EGFR Mutation Test for the treatment of non-small cell lung cancer. However, the high cost of Personalized Medicine stifles market growth throughout the forecast period of 2022-2029.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Personalized Medicine Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2021, North America had the largest share. This is linked to funding from large pharmaceutical companies and research organisations. All types of ailments are now best treated with personalised medicine, which is why drug discovery and research into any condition now include it. In the region, personalised medicine is advancing for diagnostic purposes. Due to rising demand for personalised diagnostics and novel treatment medications to combat the region's rising disease prevalence, Asia Pacific is anticipated to have the fastest expanding segment over the course of the projection year.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nGE Healthcare\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nASURAGEN, INC.\u003cbr\u003e\nAbbott\u003cbr\u003e\nDako A\/S\u003cbr\u003e\nExact Sciences Corporation\u003cbr\u003e\nDanaher Corporation (Cepheid, Inc.)\u003cbr\u003e\nDecode Genetics, Inc.\u003cbr\u003e\nQIAGEN\u003cbr\u003e\nExagen Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\n? In order to create personalised nutrition for healthcare providers and their subjects using a high-end technology interface, Panaceutics Nutrition and Viocare announced a collaborative agreement in January 2022. This agreement will combine Viocare's nutrition assessment software with personalised nutrition supplementation to create an end-to-end service platform.\u003cbr\u003e\n? Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) in Germany joined up in February 2022 to apply precision medicine in healthcare in strategic, structural, and content-specific ways.\u003cbr\u003e\nGlobal Personalized Medicine Market Report Scope:\u003cbr\u003e\nHistorical Data 2019-2020-2021\u003cbr\u003e\nBase Year for Estimation 2021\u003cbr\u003e\nForecast period 2022-2029\u003cbr\u003e\nReport Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered Product, Region\u003cbr\u003e\nRegional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World\u003cbr\u003e\nCustomization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional \u0026amp; segment scope*\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:\u003cbr\u003e\nBy Product:\u003cbr\u003e\nPersonalized Medicine Diagnostics\u003cbr\u003e\nPersonalized Medicine Therapeutics\u003cbr\u003e\nPersonalized Medical Care\u003cbr\u003e\nPersonalized Nutrition \u0026amp; Wellness\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003cbr\u003e\nNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003cbr\u003e\nEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003cbr\u003e\nLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003cbr\u003e\nRest of the World\u003c\/p\u003e\n\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nGE Healthcare\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nASURAGEN, INC.\u003cbr\u003e\nAbbott\u003cbr\u003e\nDako A\/S\u003cbr\u003e\nExact Sciences Corporation\u003cbr\u003e\nDanaher Corporation (Cepheid, Inc.)\u003cbr\u003e\nDecode Genetics, Inc.\u003cbr\u003e\nQIAGEN\u003cbr\u003e\nExagen Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 200 Pages \/ MCW16229323","offer_id":47646938366258,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-personalized-medicine-market-size-study-forecast-by-product-personalized-medicine-diagnostics-personalized-medicine-therapeutics-personalized-medical-care-personalized-nutrition-wellness-and-regional-analysis-2022-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}